Diffuse Large B Cell Lymphoma Clinical Trials in Shanghai, Shanghai Municipality
14 recruitingShanghai, Shanghai Municipality, China
Showing 1–14 of 14 trials
Recruiting
Phase 2Phase 3
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Diffuse Large B Cell LymphomaDLBCL
Merck Sharp & Dohme LLC290 enrolled132 locationsNCT05139017
Recruiting
Phase 3
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Diffuse Large B Cell Lymphoma
Merck Sharp & Dohme LLC1,046 enrolled263 locationsNCT06717347
Recruiting
Phase 1Phase 2
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+6 more
BeOne Medicines645 enrolled130 locationsNCT05006716
Recruiting
Phase 3
The Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low Risk
Diffuse Large B Cell Lymphoma
Ruijin Hospital640 enrolled1 locationNCT05018520
Recruiting
Phase 2
R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS Relapse
Diffuse Large B Cell Lymphoma
Fudan University83 enrolled2 locationsNCT05257018
Recruiting
Phase 2
Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)
Diffuse Large B Cell Lymphoma
Sun Yat-sen University42 enrolled2 locationsNCT06517511
Recruiting
Phase 1Phase 2
Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.90 enrolled25 locationsNCT06829771
Recruiting
Phase 2
Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL
Diffuse Large B Cell Lymphoma
Ruijin Hospital152 enrolled1 locationNCT06803693
Recruiting
Study on Predicting Response to Standard First-Line Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Using ctDNA Combined With PET
Diffuse Large B Cell LymphomaDLBCL
Fudan University300 enrolled1 locationNCT07070648
Recruiting
Phase 2
Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous Transplantation
Diffuse Large B Cell Lymphoma
Fudan University130 enrolled1 locationNCT07001540
Recruiting
Real-World Study of DLBCL With Different Genetic Subtypes
DLBCL - Diffuse Large B Cell LymphomaLymphoma
Ruijin Hospital10,000 enrolled1 locationNCT06026488
Recruiting
Phase 2
Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell Lymphoma
Diffuse Large B Cell Lymphoma
Ruijin Hospital76 enrolled1 locationNCT05348213
Recruiting
Phase 2
Zanubrutinib+Lenalidomide+R-ICE in Relapsed/Refractory DLBCL
Diffuse Large B-cell Lymphoma RecurrentDiffuse Large B Cell Lymphoma Refractory
RenJi Hospital20 enrolled1 locationNCT06033820
Recruiting
Phase 3
Genotype-guided Treatment in DLBCL
Diffuse Large B Cell Lymphoma
Ruijin Hospital1,100 enrolled1 locationNCT05351346